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Ochronosis is the process in Alkaptonuria (AKU) that causes all the debilitating morbidity. The 20 
process involves selective deposition of homogentisic acid-derived pigment in tissues altering 21 
the properties of these tissues, leading to their failure. Some tissues like cartilage are more 22 
easily affected by ochronosis while others such as the liver and brain are unaffected for reasons 23 
that are still not understood. In vitro and mouse models of ochronosis have confirmed the dose 24 
relationships between homogentisic acid and ochronosis and also their modulation by HPPD 25 
inhibition. Ochronosis cannot be fully reversed and is a key factor in influencing treatment 26 
decisions. Earlier detection of ochronosis preferably by non-invasive means is desirable. A 27 
cause-effect relationship between HGA and ochronosis is discussed. The similarity in AKU 28 
and familial hypercholesterolaemia is explored, and lessons learnt. More research is needed to 29 
more fully understand the crucial nature of ochronosis.  30 
 31 
  32 
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Introduction: Archibald Garrod is the father of inborn errors of metabolism and studied four 33 
disorders, namely alkaptonuria, pentosuria, cystinuria and albinism. Pentosuria 34 
(OMIM#260800) is a defect in l-xylulose reductase, necessary for xylitol metabolism, leading 35 
to overproduction of pentose sugars and pentosuria, but is otherwise harmless as it does not 36 
accumulate in the body or produce a disease process of its own (Knox 1958). This is unlike 37 
alkaptonuria (AKU) (Figure 1) (OMIM#203500) where ochronosis is the key 38 
pathophysiological event (Garrod 1902; Galdston et al. 1952; O’Brien et al. 1963). Ochronosis-39 
like processes have also been described in non-AKU states and termed pseudo-ochronosis or 40 
exogenous ochronosis (as opposed to endogenous ochronosis in AKU). Exogenous ochronosis 41 
has been the subject of previous reviews and will not be discussed further here (Levin and 42 
Maibach 2001; Bhattar et al. 2015).   43 
 44 
Ochronosis is the term used to describe a process by which a yellowish (ochre) discoloration 45 
develops (Figure 2A), due to the deposition of pigment. First described by Rudolf Virchow in 46 
1866, ochronosis was observed in miscroscopic examination of connective tissues (Virchow 47 
1866).  The tissues affected by ochronosis macroscopically, however, appear to be blue grey 48 
or black when large amounts of pigment are present. Virchow noticed that the pigment also 49 
specially accumulated in damaged or inflamed sites, such as irritated joint synovia and 50 
arteriosclerotic plaques. He hypothesised that non-crystalline colouring matter, whose nature 51 
was then unknown, slowly saturates the cartilage, a special target in AKU. 52 
  53 
It is now known that AKU is a condition characterised by the absence of homogentisate 54 
dioxygenase enzyme (HGD) (EC:1.13.11.5) (Figure 1) leading to an inability to metabolise 55 
homogentisic acid (HGA) (La Du et al. 1958). HGA, an intermediary in the 56 
phenylalanine/tyrosine pathway, is normally completely and rapidly metabolised to yield 57 
fumarate and acetoacetate (Phornphutkul et al. 2002). The degradation of phenylalanine (an 58 
essential amino acid) and tyrosine (a non-essential amino acid) proceeds to fumarate and 59 
acetoacetate through homogentisic acid so rapidly that in normal subjects there is no increase 60 
in circulating HGA and very little in urine (Davison et al. 2015). The HGD deficiency in AKU 61 
causes excessive HGA production, causing homogentisicaciduria, while also increasing HGA 62 
concentrations within body tissues. Alkaptonuria is an autosomal recessive disorder with a 63 
delayed slowly-progressive multisystemic damage for which there is still no approved disease 64 
modifying therapy, even though a drug called nitisinone decreases HGA (Introne et al. 2011). 65 
Although HGA by itself causes morbidity such as renal, prostate, gall bladder and salivary 66 
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stones, the main disease process leading to tissue destruction and debilitating clinical sequelae 67 
is ochronosis, the focus of this review. 68 
Formation of ochronotic pigment (OP): Overproduction of HGA: With an inability to 69 
metabolise HGA, there is an increase in whole body HGA despite massively increased renal 70 
excretion of HGA (Figure 1). The most important pathophysiological consequence in tyrosine 71 
pathway in AKU is conversion of accumulating HGA to OP. HGA is a reducing agent and 72 
especially under alkaline conditions it is itself rapidly oxidised via benzoquinone acetic acid 73 
turning solutions and tissues black (Zannoni et al. 1969). Slow spontaneous blackening of urine 74 
is usual in AKU, but adding alkali instantly turns urine black; acidifying the black urine does 75 
not return the black colour to normal, suggesting a potential irreversible change.  76 
Apparently slow formation of pigment: Despite the metabolic defect existing from birth, 77 
pigmentation of eyes and ears is slow to develop externally, taking up to two or three decades 78 
to appear, presumably a reflection of the gradual accretion of the pigment. Similarly, back and 79 
knee pain, due to development of critical ochronosis in these sites, are also apparent in the 80 
second and third decades (Cox and Ranganath 2011). Formation of OP is markedly increased 81 
in renal failure, consistent with increased retention of HGA, and accelerates severe morbidity 82 
and debility (Introne et al. 2002).  83 
Factors supporting molecular interaction of HGA with cartilage matrix (Figure 2B, C): The 84 
molecular mechanism through which HGA interacts with collagen matrix is unknown. 85 
Ultrastructural examination of pigmented cartilage showed that initial pigmentation is closely 86 
associated with the periodicity of collagen fibres. A periodic banding pattern of OP was 87 
observed on individual collagen fibres, with very early pigmentation appearing as small 88 
granules on the surface of fibres (Taylor et al. 2010b). These findings suggest that a nucleation-89 
like event underlies ochronosis, where initial granular deposits on individual collagen fibres is 90 
followed by further rapid pigment deposition (Gallagher et al. 2016). The data also suggest that 91 
collagen fibrils provide specific binding sites for pigment.  92 
Close observation of tissues obtained from AKU patients (Taylor et al. 2011b, 2012) and mice 93 
(Taylor et al. 2012; Preston et al. 2014) and in vitro (Tinti et al. 2011b) models of AKU show 94 
that cartilage is initially resistant to pigmentation. It is proposed that biomechanical and 95 
biochemical changes, such as those that occur in cartilage as part of the natural ageing process, 96 
render tissues susceptible to ochronosis. The ‘exposed collagen hypothesis’ theorises that 97 
binding sites become available for HGA following the loss of protective molecules such as 98 
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proteoglycans and glycosaminoglycans (Figure 2C) (GAGs) (Gallagher et al. 2016). In support 99 
of this hypothesis, AKU cartilage is shown to have lower levels of extractable GAGs and 100 
oligomeric matrix protein than osteoarthritic and non-osteoarthritic cartilage (Taylor et al. 101 
2017). There is also evidence that the structure and maturity of the collagen matrix can 102 
influence pigment deposition. Newly-synthesised aberrant matrix proteins in scar tissue also 103 
appear to pigment rapidly, as reported in the case of a mediastinal mass from an AKU patient 104 
(Taylor et al. 2011a). Solid-state NMR analysis of AKU articular joint cartilage also observed 105 
spectra indicative of marked collagen disorder at the atomic level (Chow et al. 2011), further 106 
supporting the idea that disruption to the collagen matrix supports OP deposition. 107 
Further work is required to elucidate a specific binding site for OP within the collagen matrix. 108 
It is also not known whether the initial binding occurs as HGA, the oxidised intermediate 109 
benzoquinoneacetic acid (BQA) or OP. 110 
Reversibility of pigment: It is currently believed that the OP process is not fully reversible, 111 
although there are indications of some reversal of pigment; the mechanism of such reversal is 112 
currently unknown (Ranganath et al. 2018). It is not known if OP process is dynamic i.e. 113 
formation and removal co-existing, although macrophages with pigment has been described in 114 
case reports (Gaines et al. 1987; Fisher and Davis 2004; Damian et al. 2013).  115 
Diet and OP: Tyrosine and phenylalanine are not limiting amino acids in the diet and are 116 
consumed in vast excess of requirement. The attempts to retard progression of AKU by 117 
reducing the amounts phenylalanine and tyrosine flux is in keeping with the belief that amounts 118 
of protein intake could influence AKU morbidity. 119 
Generation of OP in vitro and ex vivo (Figure 2D): Model systems have been developed for 120 
investigating various effects of HGA exposure under controlled conditions in vitro and ex vivo. 121 
In vitro models include human serum (Braconi et al. 2010a, 2011) and osteoblastic (cell line) 122 
and chondrocytic (cell line and isolated from human cartilage) cell cultures (Braconi et al. 123 
2010b; Tinti et al. 2010, 2011b; Braconi et al. 2012; Millucci et al. 2012; Spreafico et al. 2013; 124 
Millucci et al. 2015b; Mistry et al. 2016). Incubation of cell cultures with HGA leads to OP 125 
formation by four weeks. The amount of OP formed is proportionate to the concentrations of 126 
HGA in the medium (Tinti et al. 2011b). Ex vivo ‘organotypic’ approaches have modelled AKU 127 
by studying the effect of HGA on human cartilage explants (Tinti et al. 2011a; Millucci et al. 128 
2012; Bernardini et al. 2019). In these studies, pericellular pigmentation of cartilage explants 129 
is visible after two months of incubation with HGA (Tinti et al. 2011a).  130 
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Development of these model systems has not only been useful in studying the development of 131 
OP under controlled conditions, but also a number of other pathophysiological events closely 132 
associated with ochronosis including secondary amyloidosis (Millucci et al. 2012; Spreafico et 133 
al. 2013; Millucci et al. 2015b), perturbed redox homeostasis (Braconi et al. 2010a, b, 2011, 134 
2012, 2015; Tinti et al. 2010; Spreafico et al. 2013) and disorder of the cartilage extracellular 135 
matrix, including proteoglycan loss and collagen fibril re-arrangement (Tinti et al. 2010; 136 
Millucci et al. 2015b; Bernardini et al. 2019). Oxidative stress is a frequent and major 137 
consequence of HGA exposure in these studies, as indicated by direct oxidative modification 138 
to proteins and depletion of endogenous antioxidants such as glutathione (Braconi et al. 2010a, 139 
b, 2011, 2012, 2015; Spreafico et al. 2013). In vitro studies have also been important in firmly 140 
establishing the pro-oxidant role of ascorbic acid in the presence of HGA. These studies 141 
indicate that ascorbic acid is not efficacious as a mediator of HGA-induced oxidative stress 142 
and secondary amyloidosis, unless combined with other reducing agents (Tinti et al. 2010).  143 
Animal model of OP formation: In addition, mouse models of AKU, previously only considered 144 
to be models of AKU biochemistry, have been shown to develop OP (Taylor et al. 2012; 145 
Preston et al. 2014). Despite a marked elevation in plasma and urinary HGA, these mice do not 146 
develop the striking macroscopic ochronosis observed in adult humans, except in the kidneys 147 
after 13 months (Taylor et al. 2012). Several potential explanations for the lack of widespread 148 
macroscopic pigmentation in AKU mice have been postulated. We suggest that the most likely 149 
explanations are a) reduced joint-loading of quadrupedal mice, b) faster cellular turnover for 150 
removal of pigment and c) that the shorter lifespan of mice compared with humans might be 151 
insufficient for gross pigment deposition (Preston et al. 2014). However, pigmentation is 152 
observed in AKU mice microscopically; chondrocytes within the articular cartilage begin to 153 
show pigmentation at 15 weeks (Preston et al. 2014). This pigmentation progressively increases 154 
over the lifespan of the AKU mouse. Pigmentation of individual chondrocytes in AKU mice 155 
mirrors the focal initiation of ochronosis observed in human AKU, in which pigment deposition 156 
begins within single chondrocytes of the calcified cartilage and eventually results in 157 
widespread extracellular pigmentation (Taylor et al. 2011b). An exact serum HGA 158 
concentration threshold at which OP develops is not known, but a threshold range of 40-60 159 
µM/L has been reported in mice (Lewis 2018).   160 
In AKU mice administration of p-hydroxyphenylpyruvate dioxygenase (EC:1.13.11.27) 161 
(HPPD) inhibitors, such as nitisinone, soon after birth resulted in failure to pigment, while a 162 
similar administration of HPPD inhibitors during the middle of the life span of the mouse, when 163 
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pigmentation has already developed, prevented progression, but not reversal, of pigmentation 164 
(Keenan et al. 2015). This suggests that HPPD inhibitors, by decreasing HGA, can modify the 165 
OP process in AKU mice. 166 
Structure of OP: The classic view of OP formation: A fundamental question in understanding 167 
the process of ochronosis and the development of therapeutic interventions aimed at its 168 
prevention or potential reversal concerns the structure of OP itself. The prevailing view on the 169 
mechanism by which HGA produces OP in AKU largely comes from work carried out by 170 
Zannoni and colleagues in the 1960’s. These authors stated that guinea pig cartilage and skin 171 
contain enzymes, namely HGA polyphenol oxidases, which were shown to catalyse the in vitro 172 
oxidation of HGA into a dark, ochronotic-like pigment (Zannoni et al. 1969). BQA was 173 
demonstrated as an intermediate in the in vitro enzymatic oxidation of HGA, and it was 174 
proposed that BQA may polymerize to form OP in AKU (Zannoni et al. 1962, 1969). However, 175 
it is important to note the lack of evidence that polyphenol oxidase enzymes are expressed in 176 
human or other mammals (Taylor et al. 2016). Enzymes that can oxidise HGA, ‘HGA-177 
oxidases’, are observed in various species of bacteria known to produce ‘pyomelanin’ pigment 178 
derived from HGA (Hunter and Newman 2010; Roberts et al. 2015). In these species, HGA-179 
derived pyomelanin is thought to serve various adaptive functions including resistance to 180 
environmental stress such as UV light and oxidising agents. Subsequent research showed that 181 
HGA oxidation can occur non-enzymatically between pH 6.8 and 9.5 in the presence of oxygen 182 
(Martin and Batkoff 1987); it is still widely-stated in the literature that oxidation of HGA to 183 
benzoquinone intermediates occurs spontaneously in AKU and results in a polymeric pigment 184 
structure.  185 
An alternative view of OP chemical structure: Given the general assumption that OP is a 186 
product of HGA oxidative polymerisation, it is important to define the term ‘polymer’. The 187 
accepted definition of a polymer is a large molecule, or ‘macromolecule’, composed of multiple 188 
repeating subunits of a relatively lower molecular weight monomer (McNaught and Wilkinson 189 
2014). The classic concept of a polymer is that the monomer subunits are covalently bound 190 
(Allcock et al. 2003). 191 
Roberts et al. (2015) question the widely-held assumption that OP is polymeric. These authors 192 
cite the lack of conclusive evidence for this in the literature, and make the point that a polymeric 193 
structure is not necessarily required to produce the visual properties of a dark pigment; there 194 
are numerous examples of low molecular weight biological pigments. More recent analysis of 195 
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synthetically-derived OP solutions using size exclusion chromatography suggest that OP has 196 
greater molecular weight than HGA, as indicated by a peak at shorter retention time. However, 197 
visually pigmented solutions could be formed from HGA (over a shorter period of time; 10 198 
days as opposed to 2 years) without evidence of the peak corresponding to OP and no observed 199 
decrease in the HGA peak (Taylor and Vercruysse 2017). This suggests that the visual 200 
darkening of the solution due to increased pH can be due to presence of the low molecular 201 
weight oxidised form of HGA over a relatively shorter period. 202 
OP has been referred to as ‘melanin-like’ in the literature (Roberts et al. 2015); largely because 203 
melanin is another dark biological pigment derived from tyrosine and classically considered to 204 
be formed by polymerisation. However there is a growing body of evidence that melanin and 205 
OP are not covalently bound structures, and that their macromolecules do not comprise 206 
regularly repeating monomers. A recent study reports data from physicochemical analyses on 207 
the ‘pyomelanin’ pigment produced in the bacteria rubrivivax benzoatilyticus (strain JA2) 208 
(Mekala et al. 2019). This bacteria mirrors the conditions of OP pigment production in AKU; 209 
absence of the HGD gene causes accumulation of HGA, resulting in a brown pigment under 210 
aerobic conditions and in the presence of phenylalanine (Mekala et al. 2018). Fourier-transform 211 
infrared spectroscopy (FTIR) showed a range of band stretching vibrations indicating various 212 
chemical groups (aromatic and aliphatic C-H stretches, phenolic C-O stretches, aromatic ring 213 
C=C bonds, and C=O stretches due to –COOH groups) characteristic of a pigment structure 214 
derived from HGA. X-ray diffraction spectra of the pigment showed similar characteristics to 215 
that of melanin, with broad diffraction indicating an ‘amorphous’ compound structure. The 216 
absorbance spectra showed a broad band at wavelengths 280-350 nm, with increased general 217 
absorbance across the UV-visual range without distinct peaks. Similar absorbance properties 218 
have been reported previously for OP (Roberts et al. 2015; Taylor and Vercruysse 2017) and 219 
also melanin (eumelanin derived from 5,6,-dihydroxyindole-2-carboxylic acid; Tran et al. 220 
2006), and are thought to reflect a chemically heterogeneous structure of oligomers formed by 221 
a range of different bonding mechanisms, also referred to as ‘chemical disorder’ (Riesz 2007). 222 
These absorbance properties might also account for the physical appearance of some pigmented 223 
substances, which in the case of melanin is thought to provide its physiologically important 224 
optical characteristics, i.e. its ability to absorb UV light (Chen et al. 2014; Roberts et al. 2015). 225 
In contrast, specific, well-defined chemical signatures have been obtained for BQA, the 226 
proposed low molecular weight oxidation product of HGA. Specific visual-range absorbance 227 
peaks corresponding to BQA have been reported in a series of publications by Tokuhara and 228 
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colleagues. These peaks were observed at 406 and 430 nm from analysis of solutions of HGA 229 
or AKU urine following alkalinisation (Tokuhara et al. 2014, 2018) although other authors have 230 
been unable to replicate these findings (Roberts et al. 2015). Specific BQA signals were also 231 
recently reported by Tokuhara et al. (2018) from LC-QTOF-MS and NMR analyses. 232 
Computational analyses of eumelanin support a structure formed by stacked eumelanin 233 
protomolecules with random-like arrangement; in other words loosely-bound aggregates as 234 
opposed to a covalent polymer (Chen et al. 2014). This aggregate structure of melanin is further 235 
supported by mass spectrometric and spectrophotometric analyses indicating a possible 236 
formation mechanism by self-aggregation of L-dopa by a combination of non-covalent 237 
mechanisms including hydrogen bonds, π- π stacking and ionic bonds (Li et al. 2015). The 238 
same aggregation was observed for other structurally similar catecholamines which, like HGA, 239 
are derived from tyrosine. In support of this data, a recent ultrafiltration study on solutions of 240 
pigment derived from synthetic HGA in our laboratory (Norman [unpublished data]) using a 241 
10,000 Da molecular-weight filter suggested a heterogeneous mixture of compounds of varying 242 
molecular weight. The filtered solution was still pigmented, although visually lighter in 243 
appearance, suggesting presence of some OP molecules >10,000 Da (Figure 5E). Together, 244 
these more recent data are inconsistent with the idea that OP or melanin are polymers 245 
comprised of regularly repeating units with distinct chemical signatures. The term ‘polymer’ 246 
therefore does not appear to accurately describe the chemical nature of OP or melanin, as 247 
currently understood.  248 
Chemical characterisation of OP in human AKU tissue: Another approach employed to study 249 
the chemical structure of OP is chemical analysis of heavily pigmented AKU cartilage samples. 250 
Solid-state NMR analyses revealed remarkably similar spectra between deeply pigmented and 251 
non-pigmented cartilage from AKU patients (Chow et al. 2011; Norman et al. 2018). The 252 
spectra were dominated by clear amino acid signals attributable to collagen protein. The 253 
absence of a specific NMR signal attributable to OP or related structures could be due to the 254 
reduced sensitivity of NMR compared with other analytical platforms such as mass 255 
spectrometry. However, with NMR signal enhancement achieved by recent developments 256 
using dynamic nuclear polarisation, Norman et al. (2018) observed the first NMR signal 257 
attributable to OP in cartilage. A signal at 116.8 ppm in the 13C spectrum (1H-13C FSLG 258 
HETCOR 2D NMR experiment) was observed from analysis of pure, dried OP derived from 259 
synthetic HGA (3-month incubation at 37°C, as above) and heavily pigmented AKU cartilage. 260 
The same signal was observed in non-ochronotic AKU cartilage but much weaker, and even 261 
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weaker in non-AKU osteoarthritic cartilage. The 2D NMR spectra were more indicative of a 262 
poly-hydroquinone versus poly-benzoquinone structure, suggesting that the final structure of 263 
OP may not be formed simply by polymerisation of the BQA intermediate. 264 
Raman spectroscopy has recently been identified as a promising analytical technique for 265 
studying the nature of OP. Studies of cartilage samples from AKU patients revealed distinct 266 
spectra for ochronotic versus non-ochronotic cartilage. Ochronotic samples were highly 267 
fluorescent and, unlike non-ochronotic samples, provided limited to no discernible Raman 268 
spectral peaks. A novel peak was obtained from the ochronotic sample that was also observed 269 
in the spectra from pigment derived from synthetic HGA (Taylor et al. 2019). The ability of 270 
Raman spectroscopy to clearly distinguish between ochronotic and non-ochronotic tissue 271 
warrants further study, as the technique appears to have potential to provide fundamental 272 
information on the chemical nature of OP. Furthermore, there is potential for the technique to 273 
be employed as an in vivo tool for measuring and monitoring ochronosis progression in a 274 
clinical setting (Taylor et al. 2019). 275 
Distribution of ochronosis is not uniform (Table 1; Figures 3, 4): At post-mortem, pigment 276 
is patchy and present in areas of stress/damage in non-cartilaginous tissues, suggesting that 277 
‘damaged’ tissue undergoes pigmentation whereas ‘undamaged’ tissue is resistant to 278 
pigmentation; all cartilage is more consistently and highly pigmented, but also unevenly 279 
(Helliwell et al. 2008). Possible factors involved in ‘damaging’ tissues and producing pigment 280 
are shown in Table 1. It is not known if the OP structure is similar in nature in these diverse 281 
areas. Despite the constant exposure of all body tissues to HGA in AKU, most tissues are 282 
resistant to pigmentation.  283 
Cartilages are especially affected, and these include highly loaded tissues such as articular 284 
cartilage, fibrocartilage (intervertebral discs, pubic symphysis), costochondral, as well as less 285 
stressed cartilage in the pinna and nose, and the trachea-bronchial system (Helliwell et al. 286 
2008). Highly stressed tissues such as joints, spine, tendons and ligament are pigmented. OP 287 
has been noticed in the skin, especially at the interface of the palmar and dorsal skin of the 288 
hands, possibly sites of greater stress (Vijaikumar et al. 2000). Pigmentation of the nails of the 289 
hands and feet has been described. Secretory glands in the axilla, groin and eyelids pigment 290 
(Srsen et al. 1982). Ocular tissues, the conjunctivum, cornea and sclera, pigment in the second 291 
and third decade. Ochronosis has been observed in the tympanic membrane and ear wax. 292 
Cardiac valves are affected by OP more in left side of heart, and aortic more than mitral valve 293 
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(Helliwell et al. 2008); the pulmonary vascular system and the right side of the heart is much 294 
less pigmented. Pigmentation can be observed in the arterial system, mostly around branch 295 
points and tributaries, areas of greater stress (Helliwell et al. 2008). There is currently no 296 
information on pigmentation in the venous system. Renal parenchyma, especially the medulla 297 
and pyramidal tissues, show OP. The periosteum has been shown to pigment but not the bone 298 
itself, raising the possibility of bone mineral binding to collagen preventing HGA-derived 299 
molecules from binding. Teeth enamel have been said to pigment, but needs more evidence 300 
given that bone does not pigment (Siekert and Gibilisco 1970). It is generally held that muscle, 301 
liver, lung (excluding the bronchial system) and brain are not affected by OP. There is no 302 
convincing description of gastrointestinal and genital pigmentation. There is no description of 303 
pigment in pancreas, an organ where alkaline secretions are produced unlike the salivary gland. 304 
It is not known if there is biliary excretion of HGA, even though pigmented gall stones make 305 
this likely. Paucicellular tissues such as cartilage, tendon and ligament appear to pigment easily 306 
compared to highly cellular tissues such as liver. 307 
It is likely that HGA is increased in the CSF, tears and saliva although direct evidence is 308 
lacking. Circulating HGA is well characterised but tissue HGA, i.e. intracellular HGA, has not 309 
been directly assessed. It is likely HGA (and other metabolite acids) is protein-bound but 310 
requires characterisation.  311 
Detection of ochronosis: Gross ochronosis is easily visible as blue-black pigment in tissues 312 
such as the cartilage of the ears and sclera of the eyes. Photographs of the eyes and ears have 313 
been used to follow the OP process, both in terms of understanding the natural history as well 314 
as to study the effect of reducing HGA concentrations on OP using HPPD inhibitors, and may 315 
be the most efficacious way to follow pigment change (Ranganath et al. 2018). 316 
However, to detect small amounts of pigment, more sensitive techniques are required. Such 317 
techniques can employ the property of HGA as a reducing agent and can be used in tissues in 318 
vitro and ex vivo to more easily detect the OP; one such approach employs Schmorl’s stain, a 319 
ferricyanide reduction method (Figure 5B) for tissue reducing substances, to detect 320 
microscopic OP (Tinti et al. 2011b); this supports the idea that OP originated from HGA. 321 
Biopsy of tissues such as ear cartilage reveals OP even when it is not visible externally visually 322 
through the intact skin (Vijaikumar et al. 2000). 323 
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Investigations such as arthroscopy and bronchoscopy can reveal OP and suggest diagnosis of 324 
AKU for the first time. Diagnosis due to black aorta at open heart surgery for aortic valve 325 
replacement has been made (Karavaggelis et al. 2017). Direct detection of OP in vivo by Raman 326 
spectroscopy is possible. Such a technique has been validated in ex vivo tissue (Cox et al. [in 327 
press]) and is being adapted as an in vivo technique using ear cartilage and Achilles tendon, 328 
both tissues with little subcutaneous tissue (Taylor et al. 2019).  329 
Ochronosis can be seen in ex vivo samples especially from joints and these can vary in extent 330 
and degree of pigment. The earliest pigment is articular cartilage is seen in calcified cartilage 331 
cells at the junction between the calcified cartilage and subchondral bone (Taylor et al. 2010c). 332 
Similarly, OP is found in intervertebral discs and adjacent articular cartilage (Helliwell et al. 333 
2008). Investigations such as arthroscopy and bronchoscopy can reveal OP and suggest 334 
diagnosis of AKU for the first time. Diagnosis due to black aorta at open heart surgery for 335 
aortic valve replacement has been made (Cox et al. [in press]).  336 
It would be an advantage to quantify the pigmentation in vivo but such a technique is not 337 
available at present. Availability of techniques to monitor changes in whole body pigment, 338 
increase or decrease or no change over time, would be highly informative.  339 
Magnitude of flux in OP: It can be difficult to know how much metabolite flux is taking place 340 
in the phenylalanine/tyrosine pathway as these amino acids are normally fully degraded and 341 
utilised. Justus Von Liebig’s theory of the minimum applied to dietary amino acid consumption 342 
suggests that amino acids lysine, threonine, methionine, and tryptophan are limiting in diet 343 
(Liebig 1831). Tyrosine and phenylalanine are not limiting and are therefore consumed to 344 
excess. Since only 5% of consumed phenylalanine and tyrosine are needed to meet normal 345 
needs, these surplus aromatic amino acids require degradation via HGA. An attempt has been 346 
made to quantify the flux in the pigment pathway following HPPD inhibitor therapy (Milan et 347 
al. [under review]); data suggests a large flux in the ochronotic pathway.  348 
Effect of ochronosis (Table 2): The deposition of OP in tissue including cartilage alters its 349 
material properties leading to the tissue becoming hard and brittle. The Young’s modulus is 350 
altered depending upon the degree of pigmentation in AKU. Our group has proposed a model 351 
of joint failure based on initiation of ochronosis in calcified cartilage before progressing to 352 
involve the entire cartilage and spiralling into joint failure, requiring joint replacement (Taylor 353 
et al. 2011b).  354 
13 
 
This process of ochronotic stiffening also compromises intervertebral discs and adjoining bone 355 
leading to severe spinal disease characterised by severe pain as well as kyphosis and scoliosis; 356 
spinal cord compression by involved discs can require decompressive spinal surgery. Spinal 357 
fusion can ensue in the latter stages resulting in loss of mobility and flexibility in all parts of 358 
the spine, but especially in the cervical and lumbar regions.  359 
Although all cardiac valves can show ochronosis, it is the aortic valve and the aortic root that 360 
are subject to more pigmentation resulting in severe aortic stenosis requiring valve replacement 361 
surgery. Valve replacement surgery is often hazardous due to the friable ochronotic aortic root 362 
and valve. 363 
Scleral ochronosis can distort the corneal curvature and result in astigmatism (Ranganath 364 
[unpublished observations]; Lindner and Bertelmann 2014). Ochronotic ear cartilage may be 365 
associated with pain in pinna of the ear (Ranganath [unpublished observations]). Hearing loss 366 
especially to high frequency is a feature of AKU (Pau 1984; Steven et al. 2015). Rigid 367 
articular cartilage can lead to subchondral osteopenia. Generalised osteoporosis is also noted 368 
in AKU and associated with increased fracture (Cox and Ranganath 2011). The failure of 369 
ochronotic connective tissue results in tendon ruptures, especially of the Achilles tendon, but 370 
other tendon ruptures have also been observed such as flexor and extensor foot, patellar, 371 
bicipital and gluteal regions (Manoj Kumar and Rajasekaran 2003; Ranganath and Cox 2011). 372 
Similarly ruptures of ochronotic ligaments have been described. Muscle rupture has also been 373 
reported more frequently in AKU. Stone formation featuring OP has been found in kidney, 374 
prostate, gall bladder and salivary gland, resulting in symptomatic obstruction of these organs 375 
(Taylor et al. 2010a). Renal failure can ensue both due to obstruction and renal parenchymal 376 
ochronosis, sometimes leading to fatal intractable haemolytic anaemia (Mullan et al. 2015; 377 
Davison et al. 2016).  378 
Interestingly, the frequency of atheromatous vascular disease is not increased, despite 379 
pigmentation of atherosclerosis plaques. Neo-angiogenesis has been reported in the synovia 380 
of AKU patients (Millucci et al. 2016). Millucci and colleagues propose that in AKU 381 
angiogenesis and inflammation are inter-related pathological manifestations. These authors 382 
postulate that newly-formed blood vessels provide inflammatory cells with oxygen and 383 
nutrients, resulting in the release of pro-inflammatory cytokines which support angiogenesis. 384 
In this way angiogenesis may contribute to the progression from acute to chronic 385 
inflammation in AKU, as is the case in the chronic rheumatic disease synovitis (Millucci et 386 
al. 2016). In AKU, the exact association between angiogenesis and OP specifically is not 387 
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fully understood. However, it is plausible that neo-vascularisation increases access of 388 
circulating HGA to the synovium, thereby further propagating ochronosis and associated 389 
inflammation.   390 
Despite a sedentary lifestyle imposed by the morbidity of AKU, overweight and obesity is 391 
not more common in AKU, and also consequently, there is no increased prevalence of 392 
diabetes. It is debatable whether this relates to loss of nutrient, i.e. HGA, in the urine from 393 
birth, comparable to the use of inhibitors of renal glucose transport, to induce nutrient loss, 394 
in diabetes management.  395 
 396 
Mechanism of ochronotic joint and spine disease (Figure 5C): Ageing causes changes in 397 
the composition and organization of the extracellular matrix. These include loss of 398 
proteoglycans and disruption of collagen fibrils. Trauma can exacerbate these changes. 399 
Reactive molecules attack collagen fibres lacking protective proteoglycans. In AKU, 400 
homogentisic acid is the culprit leading to ochronosis (Taylor et al. 2010b). HGA-pigment 401 
modified collagen fibres become stiffened and less resistant to mechanical loading, leading 402 
to a downward spiral of structural damage. In AKU this cascade is initiated in calcified 403 
cartilage and spreads throughout the hyaline cartilage to the articular surface. Ochronosis 404 
initiates in calcified articular cartilage, beginning with the deposition of pigment in individual 405 
chondrocytes and their territorial matrix in calcified cartilage, spreading to other chondrons 406 
in the calcified matrix, then proliferating throughout the hyaline cartilage. Ochronotic 407 
cartilage shields the underlying bone from normal mechanical loading, leading to aggressive 408 
resorption of the subchondral plate, including calcified cartilage and bone, leading to 409 
catastrophic failure of the cartilage and joint itself, with fragments of cartilage escaping into 410 
the synovial space as well as impacting into underlying trabecular bone and bone marrow 411 
(Taylor et al. 2011b).  412 
It is postulated that a similar sequence of events may also take place in the spine with OP 413 
build up in the intervertebral disc and adjacent articular cartilage, leading to increased stress 414 
in the vertebral bodies and bone loss. Direct experimental evidence for this is at present 415 
lacking. 416 
OP and amyloid: Amyloidosis involves the accumulation of normally soluble proteins into 417 
insoluble fibrillar aggregate structures. A growing literature suggests that it is a secondary 418 
effect of ochronosis in vitro (Millucci et al. 2012; Spreafico et al. 2013; Braconi et al. 2017) 419 
and in vivo (Millucci et al. 2012, 2014, 2016, 2017). A number of observations report presence 420 
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of amyloid A protein aggregates and fibrils in AKU serum and  ochronotic tissue from a number 421 
of locations including cartilage, synovia, heart, periumbrical abdominal, articular fat and labial 422 
salivary gland. Amyloidosis is well-recognised in the chronic inflammatory condition 423 
rheumatoid arthritis (Obici et al. 2009), and in AKU it is also proposed to result from oxidative 424 
protein modification due to presence of reactive oxygen species (Millucci et al. 2015a). The 425 
co-localisation of amyloid with shards of OP suggests a close association with ochronosis 426 
(Millucci et al. 2015a), although the clinical significance of amyloidosis in AKU remains 427 
unknown. In addition, the observation that OP can reverse (Ranganath et al. 2018) is difficult 428 
to explain on the basis of amyloid being the major component of pigment. 429 
Linking HGA, ochronosis and damage: The genetic defect and the disease manifestations 430 
can be linked as follows. The genetic defect in AKU leads to an increase in HGA. Ochronosis 431 
is the result of increased HGA. Ochronotic tissue breaks down causing the multisystem damage 432 
in AKU. Conversely, lowering HGA should decrease ochronosis, in turn reducing damage and 433 
tissue breakdown. 434 
Incubating osteoblastic (Figure 2D) and chrondrocytic cell lines with HGA leads to 435 
development of OP within 3 weeks (Tinti et al. 2011b). OP is seen both within and outside 436 
cells. The amount of OP formed is directly proportional to the concentration of HGA in the 437 
medium. In the AKU mouse model, OP develops by around 15 weeks increasing progressively 438 
in articular joints around the body of the mouse (Taylor et al. 2012; Preston et al. 2014). 439 
Decreasing HGA in mice by employing HPPD inhibitors prevents ochronosis when started 440 
soon after birth and arrests ochronosis when started later (Taylor et al. 2012; Preston et al. 441 
2014). In humans, the OP process is accelerated when renal failure supervenes and this also 442 
leads to more rapid clinical deterioration (Introne et al. 2002). 443 
HGA and causation of Alkaptonuria: Despite the fact that HGA is normal in those without 444 
AKU, regulators still consider HGA a biomarker of disease rather than a cause of AKU in their 445 
decisions regarding approval of drugs. Debates about causative agents in disease have raged 446 
for a long time. In the nineteenth century bacteria were blamed for causing all sorts of diseases, 447 
including alkaptonuria. A bacterium in the intestine was blamed as the culprit of the black urine 448 
of affected patients that was said to convert tyrosine to homogentisic acid. In the midst of this 449 
chaos, Robert Koch established objective rules through which a causative role could be 450 
attributed to an organism/agent/factor (Koch 1876; Brown and Goldstein 1992). We have 451 
applied Koch’s postulates to AKU as seen in Table 3.  452 
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Koch's postulates and AKU (Table 3): Over time it came to be recognized that Koch’s 453 
postulates did not comply with all situations to establish a causal relationship and other criteria 454 
have been proposed such as the Bradford-Hill criteria or Hill’s criteria for causation (Hill 455 
1965). We have applied Hill’s criteria for HGA in AKU also as shown in Table 3. It is clear 456 
that HGA conforms to the requirements for a causative molecule. 457 
Lessons for AKU from the cholesterol and atherosclerosis and cardiovascular disease 458 
(Table 4): What can AKU learn from other disorders? There are strong similarities between 459 
familial hypercholesterolaemia (FH) and AKU; both are inherited diseases that form a template 460 
for the more common conditions cardiovascular disease (CVD) and osteoarthritis, respectively. 461 
AKU and FH are present from birth but the effects are delayed. HGA is the culprit molecule in 462 
AKU, while cholesterol is the molecule in CVD. Ochronosis is the process by which HGA 463 
causes the morbidity, while the comparable process in CVD is atherosclerosis. HPPD inhibitors 464 
decrease HGA production, while HMG-CoA reductase inhibitors (statins) decrease cholesterol 465 
production. Recent data suggests partial reversibility of external ochronosis by HPPD 466 
inhibition, while data from imaging studies have shown a similar partial reversal of 467 
atherosclerosis by reducing cholesterol (Nissen et al. 1991). A study has been reported showing 468 
a slower progression of AKU using HPPD inhibition, similar to statin trials on CVD 469 
progression (Ranganath et al. 2018). However it is worth noting differences in the inheritance 470 
of AKU and FH; AKU is autosomal recessive with prevalence of 1:250,000 worldwide, 471 
whereas FH is autosomal dominant (Nordestgaard et al. 2013) and relatively more common 472 
with estimated worldwide prevalence of 1:200-300 (Vallejo-Vaz and Ray 2018). Table 4 shows 473 
the comparison between AKU and FH.  474 
It is worth emphasizing that modification of the disease process (atherosclerosis) by imaging 475 
has been used as outcomes in a number of studies in CVD. This is consistent with a proposal 476 
to similarly approve the use of modification of the OP process in AKU as acceptable outcomes 477 
in clinical interventional studies. Statins have revolutionised the management of cardiovascular 478 
disease, and in FH it has been shown that earlier use of statins at low dose is superior in 479 
prevention terms compared to use of high dose statins later on in the natural history 480 
(Nordestgaard et al. 2013). Mouse studies indicate that nitisinone treatment from soon after 481 
birth completely prevents ochronosis, the main pathophysiological process in AKU (Preston et 482 
al. 2014). 483 
Therapy and ochronosis:  484 
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Antioxidant therapy by preventing oxidation of HGA to BQA, is expected to decrease 485 
ochronosis but for reasons which are unclear antioxidant ascorbic acid therapy has no clear 486 
benefit in AKU, a condition with a proposed oxidant-damage hypothesis in terms of ochronosis 487 
formation (Roberts et al. 2015); this is analogous to the lack of efficacy of antioxidant strategies 488 
in coronary artery disease studies despite the well-validated oxidised LDL theory of 489 
atherogenesis (Ranganath et al. 2013). 490 
Lower protein intakes should also in theory be associated with less ochronosis and less 491 
morbidity in AKU. However, except occasional case reports in childhood, there is no evidence 492 
that restricting dietary protein decreases ochronosis. Anecdotally vegetarians and vegans are 493 
noted to have less ochronosis and lower morbidity but no systematic evidence exists to support 494 
low protein diet in AKU (Ranganath [unpublished observations]). All other approved therapies 495 
used in clinical practice are supportive and palliative and do not address the HGA and its effects 496 
(Ranganath et al. 2013). 497 
The use of HPPD inhibition employing nitisinone to decrease flux in the tyrosine pathway has 498 
revolutionised the treatment of hereditary tyrosinaemia (Lindstedt et al. 1992; McKiernan 499 
2013). Nitisinone was first suggested as a treatment for HGA in AKU in 1998 (Anikster et al. 500 
1998), and is now shown to be highly effective in reducing HGA despite not being approved 501 
in AKU (Ranganath et al. 2018). Nitisinone not only decreases HGA but also arrests ochronosis 502 
in mice (Preston et al. 2014). A recent publication shows photographic evidence of partial 503 
reversal of ochronosis in sclera and ear cartilage in AKU patients (Ranganath et al. 2018). 504 
The NIH carried out a nitisinone interventional study in AKU between 2005 and 2009 and 505 
showed a sustained and marked decrease in urine HGA over the 3-year duration of the study 506 
(Davison et al. 2015). However, their agreement with the regulatory agency, the FDA, to 507 
approve nitisinone for AKU, required them to show a difference in range of motion at the hip 508 
between the nitisinone-treated and untreated groups; statistical significance was not found for 509 
the range of motion comparison and the study reported inconclusive. 510 
The dose of nitisinone used in the NIH study was 2 mg daily. This same dose is being used in 511 
the NAC, as mentioned in a recent publication (Ranganath et al. 2018). Further the NAC data 512 
in the publication confirmed the biochemical efficacy of nitisinone in AKU in terms of urinary 513 
HGA, but also showed slower progression of morbidity. Finally, the NAC data showed overt 514 
partial reversal of ochronosis, the primary pathogenetic event in AKU. 515 
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It is important to note that nitisinone, while shown to be a highly effective therapy for 516 
preventing ochronosis, is not a perfect therapy in AKU. It is well recognised that nitisinone 517 
treatment results in siginificant hyper-tyrosinaemia in AKU (Phornphutkul et al. 2002) and 518 
hereditary tyrosinaemia type-I (HT-I) (Lindstedt et al. 1992; McKiernan 2013). The 519 
consequences of hyper-tyrosinaemia are not fully understood in AKU, but concerns have been 520 
raised that it may contribute to the neurodevelopmental delay observed in infants with HT-I on 521 
nitisinone therapy (McKiernan 2013). Recent analyses did not find changes to monoamine 522 
neurotransmitters in brain tissue from nitisinone-treated mice (Davison et al. 2019), although 523 
more data are required to fully ascertain the impact of hyper-tyrosinaemia on central nervous 524 
system homoeostasis. Other potential future therapies for AKU may employ approaches to 525 
directly restore HGD activity for example by enzyme replacement therapy and gene therapy. 526 
However research into these approaches is still in very early stages, and they are also not 527 
without their own concerns and challenges, for example potential off-target effects.  528 
We believe that it is time that the scientific community recognised the fundamental role played 529 
by pigmentation due to ochronosis in AKU and to take this into consideration when assessing 530 
the disease as well as effectiveness of treatments for the disease. The accumulation of HGA in 531 
AKU is comparable to the increase in xylulose in pentosuria, but unlike pentosuria where there 532 
is no syndrome associated with pentose sugar accumulation, the situation is different in AKU, 533 
a condition dominated by ochronosis. While much has been learnt about ochronosis, there still 534 
remains unanswered questions. 535 
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Table 1. Factors influencing tissue ochronotic pigmentation 794 
Tissue Damaging factor 
Spine intervertebral discs Weight bearing stress 
Joints Weight bearing stress, movement damage 
Tendons Tensile stresses 
Ligaments Tensile stresses 
Aortic valve Systemic blood pressure, expansile stress 
Aortic root Systemic blood pressure, expansile stress 
Arterial tree branch points Shear stress, Bernoulli effect 
Airways cartilage Expansion, lengthening and contracting 
Ear cartilage Pressure on ears during sleep 






Table 2. The effect of ochronosis on tissues 797 
Tissue with ochronosis Effect 
Articular cartilage Resorption of calcified articular cartilage and 
subchondral bone and joint failure 
Articular cartilage Osteopenia due to resorption activated by 
stiff pigment 
Intervertebral discs Spondylosis, fracture, osteopenia, scoliosis, 
kyphosis, cord compression, radiculopathy 
Ligament Rupture 
Aortic valve and root Aortic stenosis and Aortic rigidity 
Tendons (e.g.Achilles, foot flexor and 
extensor, patellar, gluteal, biceps) 
Rupture 
Sclera Distortion in corneal curvature; astigmatism, 
glaucoma 
Ear cartilage Possible pain in ear  
Middle/inner ear Hearing loss, ear ossicles disorder leading to 
conductive deafness and high frequency 
hearing loss 
 798 
  799 
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Table 3. Koch’s postulates and its application to Alkaptonuria 800 
Koch’s postulates rules Relevance to AKU  
The agent must be found in abundance in all 
organisms suffering from the disease, but 
should not be found in healthy organisms 
HGA found in abundance in AKU but not in 
non-AKU 
The microorganism must be isolated from a 
diseased organism and grown in pure culture. 
HGA can be isolated from AKU patients by 
preparative HPLC techniques to yield pure 
HGA. 
The cultured microorganism should cause 
disease when introduced into a healthy 
organism. 
HGA can be incubated with cell cultures and 
shown to produce the features of AKU 
namely pigment. 
The microorganism must be re-isolated from 
the inoculated, diseased experimental host 
and identified as being identical to the 
original specific causative agent. 
Producing a mutation of the HGD gene in a 
normal mouse can produce an AKU mouse 
showing high HGA. 
 
Hill’s Criteria and HGA and cause in AKU 
Bradford-Hill criteria for causation How does AKU fit in 
Strength: A small association does not mean 
that there is not a causal effect, though the 
larger the association, the more likely that it 
is causal 
Strong relationship between HGA and 
disease severity. 
Consistency: Consistent findings observed 
by different persons in different places with 
Link between HGA in AKU and disease by 
various dispersed researchers. 
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different samples strengthens the likelihood 
of an effect. 
Specificity: Causation is likely if there is a 
very specific population at a specific site and 
disease with no other likely explanation. The 
more specific an association between a factor 
and an effect is, the bigger the probability of 
a causal relationship 
Only HGA causes the disease process 
characteristic of AKU 
Temporality: The effect has to occur after 
the cause (and if there is an expected delay 
between the cause and expected effect, then 
the effect must occur after that delay) 
In mouse models where the mutation of HGD 
has been produced, HGA levels increase 
after the mutation. The disease process 
however develops after slight delay both in 
mouse and humans. 
Biological Gradient: Greater exposure 
should generally lead to greater incidence of 
the effect. However, in some cases, the mere 
presence of the factor can trigger the effect. 
In other cases, an inverse proportion is 
observed: greater exposure leads to lower 
incidence 
Places with high frequency of HGD 
mutations have high HGA and AKU disease. 
Plausibility: A plausible mechanism 
between cause and effect is helpful (but Hill 
noted that knowledge of the mechanism is 
limited by current knowledge) 
HGA can reproduce the disease process 
ochronosis in vivo and is therefore plausible. 
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Coherence: Coherence between 
epidemiological and laboratory findings 
increases the likelihood of an effect. 
The relationship between mutations of the 
HGD gene, high HGA, increasing ochronosis 
over time and increasing morbidity is 
coherent. 
Experiment: Occasionally it is possible to 
appeal to experimental evidence 
Tissues exposed to HGA produce a similar 
disease process to naturally occurring 
condition AKU 
Analogy: The effect of similar factors may 
be considered 
HGA in AKU is similar to cholesterol in 
atheromatous coronary disease. 
 801 
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Frequency Heterozygote 1 in 500  
Homozygote 1 in 1,000,000 
Heterozygote 1 in 500 
Homozygote 1 in 1,000,000 




Genetic defect  LDL receptor, Apo-B defects, 
PCSK9 mutations  
HGD mutations 
Disease process Atherosclerosis Ochronosis 
Main consequence Atherosclerosis Ochronosis 
Main disease Myocardial infarction  Spondyloarthropathy 
Childhood Minimal disease Minimal disease 
Latent period 40 -50 years in heterozygous 
20 years in homozygous 
20-30y  
Prevention Yes, lifestyle and statins Nitisinone 
Lifestyle factors Yes, hypertension, physical 
activity, Smoking, diabetes, 
others 
Diet, activity, occupation 
Disease modifying therapy HMG CoA inhibitors (Statins), 
others 
HPPD inhibitors, Nitisinone 
Reversibility Partial Partial 
Earlier treatment beneficial Yes Probably yes, mouse data 
  804 
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Legend to Figures 805 
Figure 1. Tyrosine metabolic pathway – highlighting (1) the metabolic fate of tyrosine in 806 
health, (2) site of the enzyme defect observed in Alkaptonuria, homogentisate dioxygenase 807 
(HGD EC 1.13.11.5) and Hereditary Tyrosinaemia type 1, maleylacetoacetate isomerase 808 
(MAI EC 5.2.1.2), and (3) the site where nitisinone inhibits 4-hydroxyphenylpyruvate 809 
dioxygenase (HPPD EC 1.13.11.27) activity 810 
Figure 2. Ochronotic pigmentation features (1). A. Ochre or yellowish discoloration due to 811 
ochronotic pigment in the unstained ear cartilage in two patients with alkaptonuria; less in left 812 
panel, more in right panel. B. TEM image of ochronotic ligamentous capsule. Collagen fibres 813 
in longitudinal section show a distinct electron-dense pigment on their surface. Not all fibres 814 
present with pigment deposition. Numerous pigment shards can be seen on single fibres. 815 
Gradient of pigmentation can be seen running left (no pigment on fibres) to right (large 816 
electron-dense shards replacing fibres). Arrows indicate a distinct periodic binding pattern 817 
associated with pigment granules on a single fibre. C. Schematic representation of the 818 
development of ochronosis. Genetic lack of homogentisate 1,2-dioxygenase leads to an 819 
increase in concentration of homogentisic acid (HGA). HGA, its oxidation product, 820 
benzoquinone acetic acid or the final product ochronotic pigment binds to collagenous 821 
matrices. Initially, matrix is resistant to pigmentation, but following loss or breakdown of 822 
specific constituents, including proteoglycans (PG), HGA-associated compounds access 823 
binding sites which are associated with the ultrastructural periodicity of the collagen fibrils. It 824 
is proposed that the initial binding event initiates ochronosis and that the process of 825 
widespread joint pigmentation occurs over time. Pigmentation increases the stiffness of the 826 
collagen fibres, which leads to further biomechanical and biochemical damage and a 827 
downward spiral of ochronosis and tissue destruction. D. Schmorl’s staining of HGA-derived 828 
pigment deposits in cultures of SaOS-2 cells. E. Samples obtained during ultrafiltration of 829 
solutions of ochronotic pigment formed via incubation of an aqueous solution of HGA (10 830 
mmol/L) at 37 °C for 3 months. Solutions 1 and 2 are samples pre- and post-centrifugation 831 
(10 min at 2500 x g) respectively. The pigment solution was filtered using an Amicon 832 
Ultracel 10 K filter (Merck Millipore) by centrifugation (10 min at 2500 x g). Solution 3 is 833 
taken from the portion of the solution that had not passed the filter after 10 min 834 
centrifugation. Solution 4 is a sample of the filtrate and is visibly lighter in colour, indicating 835 
that the 10 K filter had retained some of the pigment. 836 
Figure 3. Ochronotic pigmentation features (2). A. Dark urine of AKU. B. External ear 837 
cartilage pigmentation. C. Dark pigmentation of temporal aspect of sclera in right eye with 838 
vessels coursing superficial to pigmentation. D. Unstained cut section of femur condyle 839 
showing little pigment on left side progressing to full thickness on the right side. E. 840 
Longitudinal cut section of abdominal aorta and common iliac bifurcation, showing more 841 
pigment at bifurcation and branch point orifices. F. Pigment at junction of palmer and dorsal 842 
skin of hands. 843 
Figure 4. Ochronotic pigmentation features (3). A. Markedly ochronotic bulging 844 
intervertebral discs and vertebral body seen from within abdominal cavity. B. Spine seen 845 
from posterior or dorsal aspect showing ochronotic pigment. C. Dark pigmentation seen in 846 
arthroscopy of knee joint showing fibrillar blackened cartilage. D. Appearance of pigmented 847 
head of femur showing uniform pigmentation. E. Hip joint showing rim of cartilage and 848 
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marked cartilage loss with exposure of underlying bone. F. Low pressure pulmonary trunk 849 
and valve showing little pigment. G. Aortic root and valve with marked pigmentation. 850 
Figure 5. Presence of ochronotic pigment in the knee joint and its progression in AKU. A. 851 
Ochronotic pigment in the joint capsule of the knee of a patient with AKU. Pigment deposits 852 
are seen as brown granules in the ECM and within fibroblasts. Section stained with nuclear 853 
fast red. B. Near serial section of the joint capsule with Schmorl’s stain. Ochronotic deposits 854 
are stained green. Bar: 50 μm. C. Schematic representation of the progression of ochronosis 855 
in articular cartilage from initiation in calcified cartilage to eventual destruction of the joint: 856 
a) ochronosis begins with the deposition of pigment in individual chondrocytes and their 857 
territorial matrix in calcified cartilage. Pigmentation leads to focal increases of stiffness 858 
altering the load distribution and inducing stress risers; b) ochronosis spreads to other 859 
chondrons in the calcified matrix, then c) proliferates throughout the hyaline cartilage; d) 860 
ochronotic cartilage shields the underlying bone from normal mechanical loading, leading to 861 
aggressive resorption of the subchondral plate, including calcified cartilage and bone; e) 862 
despite the increased stiffness, the pigmented shell of the remaining articular cartilage fails 863 
catastrophically. Pigmented cartilage becomes impacted on the underlying trabecular bone 864 
and embedded in the marrow space.  865 
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